The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: Prospective cohort study and review of the literature

Thrombosis Research

Volumn 99, Issue 1, 2000, Pages 25-34

  Douketis, James D ^a,c   Gordon, Marilyn ^a,c   Johnston, Marilyn ^a   Julian, James A ^b   Adachi, Johnathan R ^a,c   Ginsberg, Jeffrey S ^a  

^a Departments of Medicine   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Coagulation; Estrogens; Thrombophilia; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ETIDRONIC ACID; FIBRINOPEPTIDE A; PLASMINOGEN ACTIVATOR; PROTHROMBIN; THROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; THROMBOPHILIA; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADMINISTRATION, ORAL; ANTITHROMBIN III; COHORT STUDIES; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; PROSPECTIVE STUDIES; PROTHROMBIN; THROMBIN; THROMBOPHLEBITIS; VENOUS THROMBOSIS;

EID: 0033919017     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00217-6     Document Type: Article

References (41)

1. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal oestrogens. Lancet. 348:1996;981-983.
2. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
3. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., Willet W.C., Hennekens C.H. Prospective study of exogenous hormone use and risk of pulmonary embolism. Lancet. 348:1996;983-987.
4. Guttham S.P., Rodriguez L.A.G., Castellsague J., Oliart A.D. Hormone replacement therapy and risk of venous thromboembolism; population based case-control study. Br Med J. 314:1997;796-800.
5. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E., for the Heart and Estrogen/Progestin Replacement Study Group Randomized trial of estrogen plus progesterone for secondary prevention of coronary artery disease in postmenopausal women. JAMA. 280:1998;605-613.
6. Martinelli I., Bottasso B., Duca F., Faioni E. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost. 75:1996;703-705.
7. 506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost. 75:1996;270-274.
8. Ames P.R.J., Tommasino C., Iannaccone L., Brillante M., Cimino R., Brancaccio V. Coagualtion activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost. 76:1996;190-194.
9. Ginsberg J.S., Demers C., Brill-Edwards P., Johnston M., Bona R., Burrows R.F., Weitz J., Denburg J.A. Increased thrombin generation and reactivity in patients with systemic lupus erythematosus and anticardiolipin antibodies; evidence for a prothrombotic state. Blood. 81:1993;2958-2963.
10. Kyrle P.A., Stumpflen A., Hirschl M., Bialonczyk C., Herkner K., Speiser W., Weltermann A., Kaider A., Pabinger I., Lechner K., Eichinger S. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb Haemost. 78:1997;1327-1331.
11. Olivieri O., Friso S., Manzato F., Guella A., Bernardi F., Lunghi B., Girelli D., Ani M., Brocco G., Russo C., Corrocher R. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 91:1995;465-470.
12. Henkens C.M.A., Bom V.J.J., Seinen A.J., Van Der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost. 73:1995;402-404.
13. Hellgren M., Svensson P.J., Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 173:1995;210-213.
14. Cumming A.M., Tait R.C., Fildes S., Yoong A., Keeney S., Hay C.R.M. Development of resistance to activated protein C during pregnancy. Br J Haematol. 90:1995;725-727.
15. Bauer K.A., Rosenberg R.D. The pathophysiology of the prethrombotic state in humans. insights gained from studies using markers of hemostatic system activation Blood. 70:1987;343-350.
16. Wiman B., Hamsten A. The fibrinolytic system and its role in the etiology of thromboembolic disease. Sem Thromb Hemost. 16:1990;207-216.
17. Bauer K.A., Broekmans A.W., Bertina R.M., Conard J., Horellou M.H., Samama M.M., Rosenberg R.D. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood. 71:1988;1418-1426.
18. Mannucci P.M., Bottasso B., Finazzi G., De Stefano V., Palareti G., Manotti C., Mazzucconi M.G., Castaman G. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost. 67:1992;200-202.
19. Boneu B., Bes G., Pelzer H., Sie P., Boccalon H. D-dimers, thrombin-antithrombin III complexes and prothrombin fragments 1+2. diagnostic value in clinically suspected deep vein thrombosis Thromb Haemost. 65:1991;28-32.
20. Nilsson I.M., Lungner H., Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis. low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor Br Med J. 290:1990;1453-1455.
21. Didronel (etidronate sodium) tablets product monograph (package insert). Canada: Proctor and Gamble Pharmaceuticals; 1997.
22. Miller G.J., Bauer K.A., Barzegar S., Foley A.J., Mitchell J.P., Cooper J.A., Rosenberg R.D. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 73:1995;82-86.
23. Dahlback B., Hildebrand B. Inherited resistance of activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA. 91:1994;1396-1400.
24. Griffin J.H., Evatt B., Wideman C., Fernandez J.A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 82:1993;1989-1993.
25. Gebara O.C., Mittleman M.A., Walsh B.W., Lipinska I., Welty F.K., Bellotti G., Muller J.E., Sacks F.K., Tofler G.H. Fibrinolysis potential is significantly increasd by oestrogen treatment in postmenopausal women with mild dyslipidemia. Heart. 80:1998;235-239.
26. Caine Y.G., Bauer K.A., Barzegar S., ten Cate H., Sacks F.M., Walsh B.W., Schiff I., Rosenberg R.D. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 68:1992;392-395.
27. Koh K.K., Mincemoyer R., Bui M.N., Csako G., Pucino F., Guetta V., Waclawiw M., Cannon R.O. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 336:1997;683-690.
28. Conard J., Basdevant A., Thomas J.-L., Ochsenbein E., Denis C., Guyene T., Degrelle H. Cardiovascular risk factors and combined estrogen-progestin replacement therapy. a placebo-controlled study with nomogestrol acetate and estradiol Fertil Steril. 64:1995;957-962.
29. Scarabin P.-Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 17:1997;3071-3078.
30. Sporrong T., Mattson L.-A., Samsioe G., Stigendal L., Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol. 97:1990;939-944.
31. Pinto S., Bruni V., Rosati D., Prisco D., Costanza M., Giusti B., Abbate R. Effects of estrogen replacement therapy on thrombin generation. Thromb Res. 85:1997;185-193.
32. Gilabert J., Estelles A., Cano A., Espana F., Barrachina R., Grancha S., Aznar J., Tortajada M. The effects of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol. 173:1995;1849-1854.
33. Van Wersch J.W.J., Ubachs J.M.H., Van Den Ende A., Van Enk A. The effects of two regimens of hormone replacement therapy on the haemostatic profile of postmenopausal women. Eur J Chem Clin Biochem. 32:1994;449-453.
34. Boschetti C., Cortellaro M., Nencioni T., Bertolli V., Della Volpe A., Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res. 62:1991;1-8.
35. Anderson L.F., Gram J., Skouby S.O., Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol. 180:1999;283-289.
36. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457.
37. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary artery disease. A quantitative assessment of the epidemiologic evidence Prev Med. 20:1991;47-63.
38. Barrett-Connor E., Bush T.L. Estrogen use and coronary artery disease in women. JAMA. 265:1991;1861-1867.
39. Gebara O.C., Mittleman M.A., Sutherland P., Lipinska I., Matheney T., Xu P., Welty F.K., Wilson P.W., Levy D., Muller J.E.et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 91:1995;1952-1958.
40. Anderson F.A., Brownell Wheeler H., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B., Forcier A., Dalen J.E. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 151:1991;931-938.
41. Nordstrom M., Lindblad B., Bergqvist D., Kjellstrom T. A prospective study of the incidence of deep vein thrombosis in a defined urban population. J Gen Intern Med. 232:1992;155-160.